Abstract
Porcine circovirus type 2 (PCV2)-associated diseases have led to huge economic losses in pig industry. Our laboratory previously found that conjugation of chitosan oligosaccharides (COS) enhanced the immunogenicity of PCV2 vaccine against infectious pathogens. In this study, an effective adjuvant system was developed by covalent conjugation of COS via a carrier protein (Ovalbumin, OVA) to further increase the immunogenicity of vaccine. Its effect on dendritic cells maturation was assessed in vitro and its immunogenicity was investigated in mice. The results indicated that, as compared to the PCV2 and COS-PCV2, COS-OVA-PCV2 stimulated dendritic cells to express higher maturation markers (CD80, CD86, CD40 and MHC class II) and remarkably promoted both humoral and cellular immunity against PCV2 by enhancing the lymphocyte proliferation and inducing a mixed Th1/Th2 response, including the increased production of PCV2-specific antibodies and raised levels of inflammatory cytokines. Furthermore, it displayed better immune-stimulating effects than the physical mixture of vaccine and ISA206 (a commercialized adjuvant). In conclusion, conjugation of COS via a carrier protein might be a promising strategy to enhance the immunogenicity of vaccines.
Similar content being viewed by others
References
Chang, S.L., Chang, C.L., Chiang, Y.M., Hsieh, R.H., Tzeng, C.R., Wu, T.K., Sytwu, H.K., Shyur, L.F., Yang, W.C.: A review of porcine circovirus 2-associated syndromes and diseases. Vet. J. 169(3), 326–336 (2005)
Pablo, A., Jonathan, R., Barbara, W.: Cost of post-weaning multi-systemic wasting syndrome and porcine circovirus type-2 subclinical infection in England – an economic disease model. Prev. Vet. Med. 110(2), 88 (2013)
Zhang, G., Jia, P., Cheng, G., Jiao, S., Ren, L., Ji, S., Hu, T., Liu, H., Du, Y.: Enhanced immune response to inactivated porcine circovirus type 2 (PCV2) vaccine by conjugation of chitosan oligosaccharides. Carbohydr. Polym. 166, 64 (2017)
Zhang, G., Cheng, G., Jia, P., Jiao, S., Feng, C., Hu, T., Liu, H., Du, Y.: The positive correlation of the enhanced immune response to PCV2 subunit vaccine by conjugation of chitosan oligosaccharide with the deacetylation degree. Marine Drugs. 15(8), 236 (2017)
Slütter, B., Soema, P.C., Ding, Z., Verheul, R., Hennink, W., Jiskoot, W.: Conjugation of ovalbumin to trimethyl chitosan improves immunogenicity of the antigen. J. Control. Release. 143(2), 207–214 (2010)
Maurer, T., Heit, A., Hochrein, H., Ampenberger, F., O'Keeffe, M., Bauer, S., Lipford, G.B., Vabulas, R.M., Wagner, H.: CpG-DNA aided cross-presentation of soluble antigens by dendritic cells. Eur. J. Immunol. 32(8), 2356–2364 (2015)
Mellman, I., Coukos, G., Dranoff, G.: Cancer immunotherapy comes of age. Nat. Clin. Pract. Oncol. 2(3), 115 (2011)
Mancini, R.J., Tom, J.K., Esserkahn, A.P.: Covalently coupled immunostimulant heterodimers. Angew. Chem. Int. Ed. Eng. 53(1), 189–192 (2014)
Huang, Q., Yu, W., Hu, T.: Potent antigen-adjuvant delivery system by conjugation of Mycobacterium tuberculosis Ag85B-HspX fusion protein with arabinogalactan-poly(I:C) conjugate. Bioconjug. Chem. 27(4), 1165 (2016)
Wang, L., Feng, S., An, L., Gu, G., Guo, Z.: Synthetic and immunological studies of mycobacterial Lipoarabinomannan oligosaccharides and their protein conjugates. J. Organomet. Chem. 80(20), 10060–10075 (2015)
Micoli, F., Romano, M.R., Tontini, M., Cappelletti, E., Gavini, M., Proietti, D., Rondini, S., Swennen, E., Santini, L., Filippini, S.: Development of a glycoconjugate vaccine to prevent meningitis in Africa caused by meningococcal serogroup X. Proc. Natl. Acad. Sci. U. S. A. 110(47), 19077 (2013)
Verez-Bencomo, V., Fernández-Santana, V., Hardy, E., Toledo, M.E., Rodríguez, M.C., Heynngnezz, L., Rodriguez, A., Baly, A., Herrera, L., Izquierdo, M.: A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b. Science. 305(5683), 522 (2004)
Munro, C.A., Xin, H., Cartmell, J., Bailey, J.J., Dziadek, S., Bundle, D.R., Cutler, J.E.: Self-Adjuvanting Glycopeptide conjugate vaccine against disseminated candidiasis. PLoS One. 7(4), e35106 (2012). https://doi.org/10.1371/journal.pone.0035106
Gause, K.T., Wheatley, A.K., Cui, J., Yan, Y., Kent, S.J., Caruso, F.: Immunological principles guiding the rational Design of Particles for vaccine delivery. ACS Nano. 11(1), 54 (2017)
Yue, H., Wei, W., Yue, Z., Lv, P., Wang, L., Maaa, G.: Particle size affects the cellular response in macrophages. Eur. J. Pharm. Sci. 41(5), 650 (2010)
Tontini, M., Berti, F., Romano, M.R., Proietti, D., Zambonelli, C., Bottomley, M.J., De, G.E., Del, G.G., Rappuoli, R., Costantino, P.: Comparison of CRM197, diphtheria toxoid and tetanus toxoid as protein carriers for meningococcal glycoconjugate vaccines. Vaccine. 31(42), 4827–4833 (2013)
Mwirigi, M., Nkando, I., Olum, M., Attahpoku, S., Ochanda, H., Berberov, E., Potter, A., Gerdts, V., Perezcasal, J., Wesonga, H.: Capsular polysaccharide from mycoplasma mycoides subsp. mycoides shows potential for protection against contagious bovine pleuropneumonia. Vet. Immunol. Immunopathol. 178, 64 (2016)
Xu, M., Xing, X., Wu, Z., Du, Y., Hu, T.: Molecular shape and immunogenicity of meningococcal polysaccharide group a conjugate vaccine. Vaccine. 33(43), 5815–5821 (2015)
Stefanetti, G., Rondini, S., Lanzilao, L., Saul, A., Maclennan, C.A., Micoli, F.: Impact of conjugation chemistry on the immunogenicity of S. Typhimurium conjugate vaccines. Vaccine. 32(46), 6122 (2014)
Qiao, W., Ji, S., Zhao, Y., Hu, T.: Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine. Vaccine. 33(17), 2066 (2015)
Wan, X., Zhang, J., Yu, W., Shen, L., Ji, S., Hu, T.: Effect of protein immunogenicity and PEG size and branching on the anti-PEG immune response to PEGylated proteins. Process Biochem. 52, 183–191 (2017)
Hu, T., Li, D., Wang, J., Wang, Q., Liang, Y., Su, Y., Ma, G., Su, Z., Wang, S.: Propylbenzmethylation at Val-1(α) markedly increases the tetramer stability of the PEGylated hemoglobin: a comparison with propylation at Val-1(α). Biochim. Biophys. Acta. 1820(12), 2044 (2012)
Donadei, A., Balocchi, C., Mancini, F., Proietti, D., Gallorini, S., O'Hagan, D.T., D'Oro, U., Berti, F., Baudner, B.C., Adamo, R.: The adjuvant effect of TLR7 agonist conjugated to a meningococcal serogroup C glycoconjugate vaccine. Eur. J. Pharm. Biopharm. 107, 110 (2016)
Gindy, M.E., Ji, S., Hoye, T.R., Panagiotopoulos, A.Z., Prud’Homme, R.K.: Preparation of poly(ethylene glycol) protected nanoparticles with variable bioconjugate ligand density. Biomacromolecules. 9(10), 2705–2711 (2008)
Gómezlaguna, J., Salguero, F.J., Pallarés, F.J., Fernández, D.M.M., Barranco, I., Cerón, J.J., Martínezsubiela, S., Van, R.K., Carrasco, L.: Acute phase response in porcine reproductive and respiratory syndrome virus infection. Comp. Immunol. Microbiol. Infect. Dis. 33(6), e51 (2010)
Petrovsky, N.: Comparative safety of vaccine adjuvants: a summary of current evidence and future needs. Drug Saf. 38(11), 1059 (2015)
Singh, M., O'Hagan, D.: Advances in vaccine adjuvants. Nat. Biotechnol. 17(11), 1075 (1999)
Liu, X., Zhang, H., Gao, Y., Zhang, Y., Wu, H., Zhang, Y.: Efficacy of chitosan oligosaccharide as aquatic adjuvant administrated with a formalin-inactivated Vibrio anguillarum vaccine. Fish Shellfish Immunol. 47(2), 855–860 (2015)
Yeh, M.Y., Wu, M.F., Shang, H.S., Chang, J.B., Shih, Y.L., Chen, Y.L., Hung, H.F., Lu, H.F., Yeh, C., Wood, W.G.: Effects of chitosan on xenograft models of melanoma in C57BL/6 mice and hepatoma formation in SCID mice. Anticancer Res. 33(11), 4867 (2013)
Dang, Y., Li, S., Wang, W., Wang, S., Zou, M., Guo, Y., Fan, J., Du, Y., Zhang, J.: The effects of chitosan oligosaccharide on the activation of murine spleen CD11c + dendritic cells via toll-like receptor 4. Carbohydr. Polym. 83(3), 1075–1081 (2011)
Jeong, E.J., Maeng, H.J., Lee, H.J., Kim, Y., Kim, C.K.: Effect of adjuvant on pharmacokinetics, organ distribution and humoral immunity of hepatitis b surface antigen after intramuscular injection to rats. Arch. Pharm. Res. 35(9), 1621–1628 (2012)
Santini, S.M., Di Pucchio, T., Lapenta, C., Parlato, S., Logozzi, M., Belardelli, F.: The natural alliance between type I interferon and dendritic cells and its role in linking innate and adaptive immunity. J. Interf. Cytokine Res. 22(11), 1071–1080 (2002)
Rossi, M., Young, J.W.: Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J. Immunol. 175(3), 1373–1381 (2005)
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu, Y.J., Pulendran, B., Palucka, K.: Immunobiology of dendritic cells. Annu. Rev. Immunol. 18(1), 767–811 (1999)
Jin, J.O., Zhang, W., Du, J.Y., Yu, Q.: Correction for Jin et al., BDCA1-positive dendritic cells (DCs) represent a unique human myeloid DC subset that induces innate and adaptive immune responses to Staphylococcus aureus infection. Infect. Immun. 83(2), 849 (2015)
Napolitani, G., Rinaldi, A., Bertoni, F., Sallusto, F., Lanzavecchia, A.: Selected toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. 6(8), 769–776 (2005)
Flach, T.L., Ng, G., Hari, A., Desrosiers, M.D., Zhang, P., Ward, S.M., Seamone, M.E., Vilaysane, A., Mucsi, A.D., Yin, F.: Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 17(4), 479 (2011)
Ismaili, J., Rennesson, J., Aksoy, E., Vekemans, J., Vincart, B., Amraoui, Z., Van, L.F., Goldman, M., Dubois, P.M.: Monophosphoryl lipid a activates both human dendritic cells and T cells. J. Immunol. 168(2), 926 (2002)
Porporatto, C., Bianco, I.D., Correa, S.G.: Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J. Leukoc. Biol. 78(1), 62 (2005)
Fu, Y., Wang, T., Xiu, L., Shi, X., Bian, Z., Zhang, Y., Ruhan, A., Wang, X.: Levamisole promotes murine bone marrow derived dendritic cell activation and drives Th1 immune response in vitro and in vivo. Int. Immunopharmacol. 31, 57–65 (2016)
Acknowledgements
We are grateful for the support by the National Key Research and Development Program of China (2017YFD0502303), and by National Natural Science Fund, China (NO. 31500747, NO. 31570801 and NO. U160820020).
Contributors
Yuguang Du and Tao Hu designed the study. Guiqiang Zhang and Peiyuan Jia were responsible for the acquisition of data. Hongtao Liu and Guiqiang Zhang interpreted the experimental data. Guiqiang Zhang and Hongtao Liu were the major contributors in drafting and revising the manuscript. Hongtao Liu was final approval of the version to be submitted. All authors read and approved the final manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
This article contains animal studies, and all animal experiment procedures were approved by the Animal Ethical Experimentation Committee of Institute of Process Engineering, Chinese Academy of Sciences (Beijing, China).
Additional information
Highlight
A conjugate was prepared by coupling COS via OVA to PCV2 vaccine.
It markedly promoted DCs maturation, up-regulating expression of surface markers.
It displayed higher immunogenicity compared to that mixing with ISA206.
Electronic supplementary material
ESM 1
(PDF 353 kb)
Rights and permissions
About this article
Cite this article
Zhang, G., Jia, P., Liu, H. et al. Conjugation of chitosan oligosaccharides via a carrier protein markedly improves immunogenicity of porcine circovirus vaccine. Glycoconj J 35, 451–459 (2018). https://doi.org/10.1007/s10719-018-9830-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10719-018-9830-y